Morgan Stanley set a €90.00 ($104.65) price target on Merck KGaA (FRA:MRK) in a research report sent to investors on Monday. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other equities analysts also recently commented on MRK. Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the company a buy rating in a research report on Wednesday, February 6th. DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a research report on Monday. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a buy rating in a research report on Tuesday, February 5th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the company a neutral rating in a research report on Tuesday, February 5th. Finally, Credit Suisse Group set a €93.00 ($108.14) target price on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of €98.80 ($114.88).
Merck KGaA stock opened at €96.44 ($112.14) on Monday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: How to interpret a stock’s beta number
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.